Chapter 083. Cancer of the Skin (Part 10) pps

Chapter 083. Cancer of the Skin
(Part 10)

Other Nonmelanoma Cutaneous Malignancies
Neoplasms of cutaneous adnexa and sarcomas of fibrous, mesenchymal,
fatty, and vascular tissues make up 1–2% of NMSC (Table 83-6). Some can
portend a poor prognosis such as Merkel cell carcinoma, which is a neural crest-
derived, highly aggressive malignancy that exhibits a metastatic rate of 75% and a
5-year survival rate of 30–40%. Others, such as the human herpes virus 8-induced,
HIV-related Kaposi's sarcoma, exhibit a more indolent course. The marked
decrease in incidence of this tumor parallels the institution of the highly active
antiretroviral therapy.
Table 83-6 Other Nonmelanoma Cutaneous Malignancies

Tumor Type Most
Common
Location
Recurrenc
e Rate,
a
%
Metastati
c Rate, %
Atypical
fibroxanthoma
Head and
neck
21 4
Merkel cell
carcinoma
Head and

neck
40 75
Dermatofibrosarcom
a protuberans
Trunk 50 1
Sebaceous
carcinoma
Eyelid 12 30
Microcystic adnexal
carcinoma
Face 50 1 case
Porocarcinoma Extremit 20 10
y
Eccrine carcinoma
Head and
neck
36 11
Angiosarcoma
Head and
neck
75 75

a
Recurrence rates are the highest reported and were established prior to
widespread use of Mohs micrographic surgery.
Acknowledgment
Katarina G. Chiller, MD, and Howard K. Koh, MD, contributed to this
chapter in the 16th edition and material from that chapter is included here
Further Readings
American Cancer Society: Website at www.cancer.org

Balch CM et al
: Prognostic factors analysis of 17,600 melanoma patients:
Validation of the American Joint Committee on Cancer melanoma staging system.
J Clin Oncol 19:3622, 2001 [PMID: 11504744]
Balch CM et al: Final version of the AJCC staging system for cutaneous
melanoma. J Clin Oncol 19:3635, 2001 [PMID: 11504745]
Drake LA et al: Guidelines of care of basal cell carcinoma. J Am Acad
Dermatol 26:117, 1992 [PMID: 1732317]
———
et al: Guidelines of care for cutaneous squamous cell carcinoma. J
Am Acad Dermatol 28:628, 1993
Geisse JK et al: Imiquimod 5% cream for the treatment of superficial basal
cell carcinoma: A double-blind, randomized, vehicle-
controlled study. J Am Acad
Dermatol 47:390, 2002 [PMID: 12196749]
Johnson TM et al: Staging workup, sentinel node biopsy, and follow-
up
tests for melanoma: Update of current concepts, Arch Dermatol 140:107, 2004
[PMID: 14732667]
Morton DL et al: Sentinel-
node biopsy on nodal observation in melanoma.
N Engl J Med 355:1307, 2006 [PMID: 17005948]
Petrella T et al: Single agent interleukin-
2 in the treatment of metastatic
melanoma: A systematic review. Cancer Treat Rev 2007 [epub ahead of print]
[PMID: 17562357]
Rigel DS et al: ABCDE: An evolving concept in the early diagnosis of
melanoma. Arch Dermatol 141:1032, 2005 [PMID: 16103334]
Tsao H et al: Management of cutaneous melanoma. N Engl J Med 351:998,
2004 [PMID: 15342808]

Bibliography
Albert L
et al: Dysplastic melanocytic nevi and cutaneous melanoma:
Markers of increased melanoma risk for affected individuals a
nd blood relatives. J
Am Acad Dermatol 7:69, 1990
Armstrong BK: Epidemiology of malignant melanoma: Intermittent or total
accumulated exposure to the sun. J Dermatol Surg Oncol 14:835, 1988 [PMID:
3397443]
Atkins MB et al: High-dose recombinant interle
ukin 2 therapy for patients
with metastatic melanoma: Analysis of 270 patients treated between 1985 and
1993. J Clin Oncol 17:2105, 1999 [PMID: 10561265]
Balch CM et al (eds): Cutaneous Melanoma
4th ed. St. Louis, Quality
Medical Publishing, 2003
Clark
WH Jr et al: The histogenesis and biologic behavior of primary
human malignant melanoma of the skin. Cancer Res 29:705, 1969 [PMID:
5773814]
Friedman RI et al (eds): Cancer of the Skin. Philadelphia, Saunders, 1991
——— et al: Malignant melanoma in the
1990s: The continued importance
of early detection and the role of physician examination and self-
examination of
the skin. CA Cancer J Clin 1:201, 1991
Kirkwood JM et al: High-
dose interferon alfa 2b significantly prolongs
relapse-free and overall survival compared with the GM2-KLH/QS-
21 vaccine in

patients with resected stage IIB-
III melanoma: Results of Intergroup Trial E
1694/S9512/C509801. J Clin Oncol 19:2370, 2001 [PMID: 11331315]
Langley RGB et al: Neoplasms: Cutaneous melanoma, in Dermatology i
n
General Medicine
, 6th ed, IM Freedberg et al (eds). New York, McGraw Hill
2003, pp 917–947
Lippman SM et al: l3-cis-retinoic acid and interferon-
a2a: Effective
combination therapy for advanced squamous cell carcinoma of the skin. J Natl
Cancer Inst 84:235, 1992 [PMID: 1734084]
Marks R: An overview of skin cancers. Incidence and causation. Cancer
75(Suppl):607, 1995
Preston DS et al: Nonmelanoma cancer of the skin. N Engl J Med
327:1649, 1992 [PMID: 1435901]
Rhodes AR: Neoplasms: Benign neoplasias,
hyperplasias, and dysplasias of
melanocytes, in Dermatology in General Medicine
, 4th ed, TB Fitzpatrick et al
(eds). New York, McGraw-Hill, 1993, pp 996–1097
Rhodes AR et al: Risk factors for cutaneous melanoma. JAMA 258:3146,
1987 [PMID: 3312689]
Rig
el DS et al: Dysplastic nevi. Matters for increased risk for melanoma.
Cancer 63:386, 1989 [PMID: 2910446]
Sober AJ, Haluska FG: Skin Cancer. Hamilton, Ont., BC Decker, 2001
Veronesi U et al: Delayed regional lymph node dissection in stage 1
melanoma o
f the skin of the lower extremities. Cancer 49:2420, 1982 [PMID:

7074555]
Veronesi U, Cascinelli N: Narrow excision (1 cm margin), a safe procedure
for thin cutaneous melanoma. Arch Surg 126:438, 1991 [PMID: 2009058]